pith. sign in

arxiv: 2505.18920 · v3 · pith:2ZWXPCG3new · submitted 2025-05-25 · 🧬 q-bio.QM · q-bio.CB

Sensitivity analysis-guided model reduction of a mathematical model of pembrolizumab therapy for de novo metastatic MSI-H/dMMR colorectal cancer

Georgio Hawi , Peter S. Kim , Peter P. Lee This is my paper

Pith reviewed 2026-05-22 01:24 UTC · model grok-4.3

classification 🧬 q-bio.QM q-bio.CB
keywords model reductionsensitivity analysisFASTEFASTpembrolizumabcolorectal cancerMSI-HdMMR
0
0 comments X

The pith

Sensitivity analysis reduces a pembrolizumab therapy model for colorectal cancer to two simpler versions that match its trajectories.

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The paper applies Fourier amplitude sensitivity testing to a detailed mathematical model of de novo metastatic MSI-H/dMMR colorectal cancer under pembrolizumab treatment. This identifies parameters and interactions that can be fixed or removed while keeping the main behaviors intact. The authors then build one reduced model that reproduces every original trajectory and a second minimal model that keeps the essential dynamics but can accept new biological components more easily. A sympathetic reader would care because these versions lower the effort needed to run many simulations or add features such as combination therapies, making it more practical to explore treatment optimization and immune dynamics.

Core claim

We used our data-driven model of de novo metastatic MSI-H/dMMR CRC and performed sensitivity analysis-guided model reduction using the Fourier amplitude sensitivity testing (FAST) and extended FAST (EFAST) methods. In this work, we constructed two simplified models of dnmMCRC: one that faithfully reproduces all of the original model's trajectories, and a second, minimal model that accurately replicates the original dynamics while being highly extensible for future inclusion of additional components to explore various aspects of the anti-tumour immune response. Together, these resulting models offer a tractable foundation for future theoretical and computational studies of immune checkpoint

What carries the argument

Fourier amplitude sensitivity testing (FAST) and extended FAST (EFAST) methods, which rank parameters and interactions by their effect on output trajectories to decide what can be simplified without changing pembrolizumab response dynamics.

If this is right

  • The simplified models provide a tractable foundation for future theoretical and computational studies of immune checkpoint blockade.
  • They avoid unnecessary complexity while preserving mechanistic interpretability.
  • The minimal model supports future inclusion of additional components to explore aspects of the anti-tumour immune response.
  • Future studies can use these reduced models in place of the full original for more efficient analysis.
  • The approach yields models suitable for both theoretical exploration and computational simulation of treatment effects.

Where Pith is reading between the lines

These are editorial extensions of the paper, not claims the author makes directly.

  • The minimal model could be paired with new clinical data sets to estimate patient-specific parameters more quickly than the full version allows.
  • The same sensitivity-guided reduction steps could be applied to mathematical models of other PD-1 inhibitors or different cancer types.
  • Extensibility of the minimal model makes it straightforward to test hypotheses about combination therapies or mechanisms of resistance not present in the original.
  • Researchers might derive reduced-order approximations or steady-state relations directly from the minimal model for analytical insight.
  • The faithful reproduction of all trajectories suggests the reduced models remain suitable for quantitative predictions of dose-response behavior.

Load-bearing premise

The sensitivity analysis methods correctly identify which parameters and interactions can be removed or fixed without materially changing the key output trajectories for pembrolizumab therapy.

What would settle it

Run both reduced models and the original model under identical initial conditions and pembrolizumab dosing schedules, then compare the time courses of tumor volume, T-cell populations, and cytokine levels; large divergence in any trajectory would show the reduction is invalid.

Figures

Figures reproduced from arXiv: 2505.18920 by Georgio Hawi, Peter P. Lee, Peter S. Kim.

Figure 1
Figure 1. Figure 1: Schematic diagram of the interactions of cancer cells, DAMPs, and DCs in the full model. [PITH_FULL_IMAGE:figures/full_fig_p012_1.png] view at source ↗
Figure 2
Figure 2. Figure 2: Schematic diagram of the interactions of T cells in the full model. [PITH_FULL_IMAGE:figures/full_fig_p014_2.png] view at source ↗
Figure 3
Figure 3. Figure 3: Schematic diagram of the interactions of macrophages and NK cells in the full model. [PITH_FULL_IMAGE:figures/full_fig_p015_3.png] view at source ↗
Figure 4
Figure 4. Figure 4: Schematic diagram of the interactions of cytokines in the full model. [PITH_FULL_IMAGE:figures/full_fig_p017_4.png] view at source ↗
Figure 5
Figure 5. Figure 5: Schematic diagram of the interactions of immune checkpoint-associated components in the [PITH_FULL_IMAGE:figures/full_fig_p018_5.png] view at source ↗
Figure 6
Figure 6. Figure 6: Schematic diagram of the interactions of immune checkpoint-associated components in the [PITH_FULL_IMAGE:figures/full_fig_p019_6.png] view at source ↗
Figure 7
Figure 7. Figure 7: Time traces of variables up to 672 days in the minimal, reduced, and full models, with the [PITH_FULL_IMAGE:figures/full_fig_p039_7.png] view at source ↗
Figure 8
Figure 8. Figure 8: Time traces of VTS up to 672 days from commencement from the minimal, reduced, and full models. Time traces from the full model are shown in black, from the reduced model in red, and from the minimal model in blue, with dashed lines indicating no treatment and solid lines indicating the standard regimen. To quantitatively evaluate how well the reduced and minimal models replicate the trajectories of the fu… view at source ↗
read the original abstract

Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide and the leading cause of cancer-related deaths in adults under 55, involving a complex interplay of biological processes such as dendritic cell (DC) maturation and migration, T cell activation and proliferation, cytokine production, and T cell and natural killer (NK) cell-mediated cancer cell killing. Microsatellite instability-high (MSI-H) CRC and deficient mismatch repair (dMMR) CRC constitute 15% of all CRC and 4% of metastatic CRC, and exhibit remarkable responsiveness to immunotherapy, especially with PD-1 inhibitors such as pembrolizumab. Mathematical models of the underlying immunobiology and the interactions underpinning immune checkpoint blockade offer mechanistic insights into tumour--immune dynamics and provide avenues for treatment optimisation and the identification of novel therapeutic targets. We used our data-driven model of de novo metastatic MSI-H/dMMR CRC (dnmMCRC) and performed sensitivity analysis-guided model reduction using the Fourier amplitude sensitivity testing (FAST) and extended FAST (EFAST) methods. In this work, we constructed two simplified models of dnmMCRC: one that faithfully reproduces all of the original model's trajectories, and a second, minimal model that accurately replicates the original dynamics while being highly extensible for future inclusion of additional components to explore various aspects of the anti-tumour immune response. Together, these resulting models offer a tractable foundation for future theoretical and computational studies of immune checkpoint blockade, avoiding unnecessary complexity while preserving mechanistic interpretability.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, simulated authors' rebuttal, and a circularity audit. Tearing a paper down is the easy half of reading it; the pith above is the substance, this is the friction.

Referee Report

3 major / 2 minor

Summary. The paper applies Fourier amplitude sensitivity testing (FAST) and extended FAST (EFAST) to a data-driven ODE model of pembrolizumab therapy in de novo metastatic MSI-H/dMMR colorectal cancer (dnmMCRC). Sensitivity rankings are used to construct two reduced models: a simplified version claimed to faithfully reproduce all original trajectories and a minimal extensible model that preserves key dynamics while facilitating future addition of immune-response components.

Significance. If the reductions are rigorously validated, the work supplies tractable, mechanistically interpretable models that lower the barrier to theoretical and computational studies of immune checkpoint blockade in MSI-H/dMMR CRC. The approach of sensitivity-guided reduction is a standard and useful technique in systems biology when accompanied by quantitative fidelity checks.

major comments (3)
  1. The central claim that the reduced models 'faithfully reproduce all of the original model's trajectories' and 'accurately replicate the original dynamics' is not supported by any reported quantitative error metrics (e.g., integrated L2 norms, maximum pointwise deviations, or relative errors) between the full and reduced systems for each state variable over the simulation horizon. Without these, the fidelity assertion remains qualitative.
  2. The reduction procedure implicitly assumes that parameters ranked low by first- and total-order EFAST indices at the nominal parameter vector and reference pembrolizumab dosing schedule can be fixed or removed without altering dynamics under therapeutic variations. In a nonlinear immune-oncology model, this assumption requires explicit verification (e.g., re-simulation under perturbed dosing or initial conditions) that is not described.
  3. No full parameter tables, nominal values used for sensitivity analysis, or ranges over which FAST/EFAST indices were computed are provided in the text. This information is load-bearing for reproducibility and for assessing whether the sensitivity rankings are robust.
minor comments (2)
  1. The abstract states the models are 'data-driven' but does not indicate the source or nature of the data used for parameterization or validation.
  2. Notation for state variables and parameters should be introduced consistently in the main text with a clear table or list of symbols.

Simulated Author's Rebuttal

3 responses · 0 unresolved

We thank the referee for their constructive comments, which highlight important aspects for improving the rigor and reproducibility of our work. We address each major comment point by point below, indicating planned revisions to the manuscript.

read point-by-point responses

  1. Referee: The central claim that the reduced models 'faithfully reproduce all of the original model's trajectories' and 'accurately replicate the original dynamics' is not supported by any reported quantitative error metrics (e.g., integrated L2 norms, maximum pointwise deviations, or relative errors) between the full and reduced systems for each state variable over the simulation horizon. Without these, the fidelity assertion remains qualitative.

    Authors: We agree that the current presentation relies primarily on visual trajectory comparisons. In the revised manuscript we will add quantitative fidelity metrics, specifically integrated L2 norms, maximum pointwise absolute deviations, and relative errors for every state variable over the full simulation horizon. These will be reported in a new table or supplementary figure for both reduced models. revision: yes

  2. Referee: The reduction procedure implicitly assumes that parameters ranked low by first- and total-order EFAST indices at the nominal parameter vector and reference pembrolizumab dosing schedule can be fixed or removed without altering dynamics under therapeutic variations. In a nonlinear immune-oncology model, this assumption requires explicit verification (e.g., re-simulation under perturbed dosing or initial conditions) that is not described.

    Authors: The referee correctly notes that global sensitivity indices alone do not automatically guarantee invariance under dosing changes in a nonlinear system. We will add explicit verification simulations in the revised manuscript: the reduced models will be re-run under clinically plausible perturbations of the pembrolizumab dosing schedule and under varied initial tumor burdens, with quantitative error metrics reported to confirm continued fidelity. revision: yes

  3. Referee: No full parameter tables, nominal values used for sensitivity analysis, or ranges over which FAST/EFAST indices were computed are provided in the text. This information is load-bearing for reproducibility and for assessing whether the sensitivity rankings are robust.

    Authors: We thank the referee for identifying this omission. The revised manuscript will contain a complete parameter table that lists every parameter together with its nominal value, units, biological meaning, and the exact sampling ranges (including distribution type) used to compute the FAST and EFAST indices. This addition will enable full reproduction of the sensitivity analysis. revision: yes

Circularity Check

0 steps flagged

No significant circularity in sensitivity-guided model reduction

full rationale

The derivation applies standard FAST/EFAST sensitivity analysis to the authors' prior model to rank parameters, then fixes or removes low-sensitivity terms and constructs two reduced ODE systems whose trajectories are compared to the original. This process relies on explicit numerical verification of trajectory fidelity rather than any self-definitional loop, fitted parameter renamed as prediction, or load-bearing self-citation chain. The original model serves as an independent input whose equations and outputs are used to compute sensitivity indices; the reduced models are new outputs whose fidelity is checked separately. No step equates the final claim to its inputs by construction.

Axiom & Free-Parameter Ledger

1 free parameters · 1 axioms · 0 invented entities

The reduction inherits all parameters and structural assumptions of the original data-driven model; sensitivity analysis is used to prune but does not eliminate the need for those upstream choices.

free parameters (1)
  • original model rate constants and initial conditions
    The base model contains multiple biological rate parameters whose values are either literature-derived or fitted; these remain in the reduced versions until explicitly fixed by sensitivity results.
axioms (1)
  • domain assumption The original mathematical model accurately captures the immunobiology of dendritic cell maturation, T-cell activation, cytokine production, and tumor cell killing under pembrolizumab in dnmMCRC.
    All downstream reduction steps presuppose that the starting model is a faithful representation of the biology.

pith-pipeline@v0.9.0 · 5821 in / 1317 out tokens · 64072 ms · 2026-05-22T01:24:43.706124+00:00 · methodology

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.

Lean theorems connected to this paper

Citations machine-checked in the Pith Canon. Every link opens the source theorem in the public Lean library.

What do these tags mean?
matches
The paper's claim is directly supported by a theorem in the formal canon.
supports
The theorem supports part of the paper's argument, but the paper may add assumptions or extra steps.
extends
The paper goes beyond the formal theorem; the theorem is a base layer rather than the whole result.
uses
The paper appears to rely on the theorem as machinery.
contradicts
The paper's claim conflicts with a theorem or certificate in the canon.
unclear
Pith found a possible connection, but the passage is too broad, indirect, or ambiguous to say the theorem truly supports the claim.

Reference graph

Works this paper leans on

54 extracted references · 54 canonical work pages · 1 internal anchor

  1. [1]

    Optimisation of pembrolizumab therapy for de novo metastatic MSI- H/dMMR colorectal cancer using data-driven delay integro-differential equations

    Hawi G, Kim PS, Lee PP. Optimisation of pembrolizumab therapy for de novo metastatic MSI- H/dMMR colorectal cancer using data-driven delay integro-differential equations. bioRxiv. 2025. Available from: https://www.biorxiv.org/content/early/2025/05/24/2025.05.23.655752

    work page 2025

  2. [2]

    Inflammatory Bowel Disease: How Effective Is TNF-α Suppression? PLOS ONE

    Lo WC, Arsenescu V, Arsenescu RI, Friedman A. Inflammatory Bowel Disease: How Effective Is TNF-α Suppression? PLOS ONE. 2016 Nov;11(11):e0165782. Available from:https://doi. org/10.1371/journal.pone.0165782

    work page doi:10.1371/journal.pone.0165782 2016

  3. [3]

    Pivotal Dose of Pembrolizumab: A Dose-Finding Strategy for Immuno-Oncology

    Li TR, Chatterjee M, Lala M, Abraham AK, Freshwater T, Jain L, et al. Pivotal Dose of Pembrolizumab: A Dose-Finding Strategy for Immuno-Oncology. Clinical Pharmacology & Ther- apeutics. 2021 Mar;110(1):200–209. Available from:https://doi.org/10.1002/cpt.2170

    work page doi:10.1002/cpt.2170 2021

  4. [4]

    Structureand Interactions of the Human Programmed Cell Death 1 Receptor

    ChengX,VeverkaV,RadhakrishnanA,WatersLC,MuskettFW,MorganSH,etal. Structureand Interactions of the Human Programmed Cell Death 1 Receptor. Journal of Biological Chemistry. 2013 Apr;288(17):11771–11785. Available from:https://doi.org/10.1074/jbc.M112.448126

    work page doi:10.1074/jbc.m112.448126 2013

  5. [5]

    Tumor size, tumor location, and antitumor inflammatory response are associated with lymph node size in colorectal cancer 34 patients

    Rössler O, Betge J, Harbaum L, Mrak K, Tschmelitsch J, Langner C. Tumor size, tumor location, and antitumor inflammatory response are associated with lymph node size in colorectal cancer 34 patients. Modern Pathology. 2017 Jun;30(6):897–904. Available from: https://doi.org/10. 1038/modpathol.2016.227

    work page 2017

  6. [6]

    Real-time Kinetics of High-mobility Group Box 1 (HMGB1) Oxidation in Extracellular Fluids Studied by in Situ Protein NMR Spectroscopy

    Zandarashvili L, Sahu D, Lee K, Lee YS, Singh P, Rajarathnam K, et al. Real-time Kinetics of High-mobility Group Box 1 (HMGB1) Oxidation in Extracellular Fluids Studied by in Situ Protein NMR Spectroscopy. Journal of Biological Chemistry. 2013 Apr;288(17):11621–11627. Available from: https://doi.org/10.1074/jbc.M113.449942

    work page doi:10.1074/jbc.m113.449942 2013

  7. [7]

    In: Cell Surface Calreticulin: Role in Signaling Throm- bospondin Anti-Adhesive Activity

    Goicoechea SM, Murphy-Ullrich JE. In: Cell Surface Calreticulin: Role in Signaling Throm- bospondin Anti-Adhesive Activity. Springer US; 2003. p. 193–204. Available from: https: //doi.org/10.1007/978-1-4419-9258-1_18

    work page doi:10.1007/978-1-4419-9258-1_18 2003

  8. [8]

    Engineering Calreticulin- Targeting Monobodies to Detect Immunogenic Cell Death in Cancer Chemotherapy

    Zhang Y, Thangam R, You SH, Sultonova RD, Venu A, Min JJ, et al. Engineering Calreticulin- Targeting Monobodies to Detect Immunogenic Cell Death in Cancer Chemotherapy. Cancers. 2021 Jun;13(11):2801. Available from:https://doi.org/10.3390/cancers13112801

    work page doi:10.3390/cancers13112801 2021

  9. [9]

    Anatomical Origin of Dendritic Cells Determines Their Life Span in Peripheral Lymph Nodes

    Ruedl C, Koebel P, Bachmann M, Hess M, Karjalainen K. Anatomical Origin of Dendritic Cells Determines Their Life Span in Peripheral Lymph Nodes. The Journal of Immunology. 2000 Nov;165(9):4910–4916. Available from:https://doi.org/10.4049/jimmunol.165.9.4910

    work page doi:10.4049/jimmunol.165.9.4910 2000

  10. [10]

    Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs

    Kamath AT, Henri S, Battye F, Tough DF, Shortman K. Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs. Blood. 2002 Sep;100(5):1734–1741. Available from: https://doi.org/10.1182/blood.V100.5.1734.h81702001734_1734_1741

    work page doi:10.1182/blood.v100.5.1734.h81702001734_1734_1741 2002

  11. [11]

    Self–class I MHC molecules support survival of naive CD8 T cells, but depress their functional sensitivity through regulation of CD8 expression levels

    Takada K, Jameson SC. Self–class I MHC molecules support survival of naive CD8 T cells, but depress their functional sensitivity through regulation of CD8 expression levels. Journal of Experimental Medicine. 2009 Sep;206(10):2253–2269. Available from:https://doi.org/10. 1084/jem.20082553

    work page 2009

  12. [12]

    Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans

    Hellerstein M, Hanley MB, Cesar D, Siler S, Papageorgopoulos C, Wieder E, et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nature Medicine. 1999 Jan;5(1):83–89. Available from:https://doi.org/10.1038/4772

    work page doi:10.1038/4772 1999

  13. [13]

    Mature Dendritic Cells May Promote High-Avidity Tuning of Vaccine T Cell Responses

    Kumbhari A, Egelston CA, Lee PP, Kim PS. Mature Dendritic Cells May Promote High-Avidity Tuning of Vaccine T Cell Responses. Frontiers in Immunology. 2020 Oct;11. Available from: https://doi.org/10.3389/fimmu.2020.584680

    work page doi:10.3389/fimmu.2020.584680 2020

  14. [14]

    Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo

    Vukmanovic-Stejic M, Zhang Y, Cook JE, Fletcher JM, McQuaid A, Masters JE, et al. Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. Journal of Clinical Investigation. 2006 Sep;116(9):2423–2433. Available from:https: //doi.org/10.1172/JCI28941

    work page doi:10.1172/jci28941 2006

  15. [15]

    The fate and lifespan of human monocyte subsets in steady state and systemic inflammation

    Patel AA, Zhang Y, Fullerton JN, Boelen L, Rongvaux A, Maini AA, et al. The fate and lifes- pan of human monocyte subsets in steady state and systemic inflammation. Journal of Experi- mental Medicine. 2017 Jun;214(7):1913–1923. Available from:https://doi.org/10.1084/jem. 20170355

    work page doi:10.1084/jem 2017

  16. [16]

    Natural killer cells in cancer biology and therapy

    Wu SY, Fu T, Jiang YZ, Shao ZM. Natural killer cells in cancer biology and therapy. Molecular Cancer. 2020 Aug;19(1). Available from:https://doi.org/10.1186/s12943-020-01238-x

    work page doi:10.1186/s12943-020-01238-x 2020

  17. [17]

    Functions of natural killer cells

    Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nature Immunology. 2008 Apr;9(5):503–510. Available from:https://doi.org/10.1038/ni1582. 35

    work page doi:10.1038/ni1582 2008

  18. [18]

    Potentiation of Natural Killer Cells for Cancer Immunotherapy: A Review of Literature

    Lowry LE, Zehring WA. Potentiation of Natural Killer Cells for Cancer Immunotherapy: A Review of Literature. Frontiers in Immunology. 2017 Sep;8. Available from:https://doi.org/ 10.3389/fimmu.2017.01061

    work page doi:10.3389/fimmu.2017.01061 2017

  19. [19]

    In vivo administration of purified human interleukin 2

    Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CA, et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. The Journal of Immunology. 1985 Oct;135(4):2865–2875. Available from:https://doi.org/10.4049/jimmunol.135.4.2865

    work page doi:10.4049/jimmunol.135.4.2865 1985

  20. [20]

    Interferon-γ-Induced Necrosis: An Antitumor Biotherapeutic Per- spective

    Balachandran S, Adams GP. Interferon-γ-Induced Necrosis: An Antitumor Biotherapeutic Per- spective. Journal of Interferon & Cytokine Research. 2013 Apr;33(4):171–180. Available from: https://doi.org/10.1089/jir.2012.0087

    work page doi:10.1089/jir.2012.0087 2013

  21. [21]

    A novel recombinant slow-release TNF α-derived peptide effectively inhibits tumor growth and angiogensis

    Ma Y, Zhao S, Shen S, Fang S, Ye Z, Shi Z, et al. A novel recombinant slow-release TNF α-derived peptide effectively inhibits tumor growth and angiogensis. Scientific Reports. 2015 Sep;5(1). Available from:https://doi.org/10.1038/srep13595

    work page doi:10.1038/srep13595 2015

  22. [22]

    Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge

    Oliver J, Bland L, Oettinger C, Arduino M, McAllister S, Aguero S, et al. Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge. Lymphokine and cytokine research. 1993 April;12(2):115—120. Available from:https://pubmed.ncbi.nlm.nih.gov/8324076/

    work page arXiv 1993

  23. [23]

    TGF-β: An Important Media- tor of Allergic Disease and a Molecule with Dual Activity in Cancer Development

    Tirado-Rodriguez B, Ortega E, Segura-Medina P, Huerta-Yepez S. TGF-β: An Important Media- tor of Allergic Disease and a Molecule with Dual Activity in Cancer Development. Journal of Im- munology Research. 2014;2014:1–15. Available from:https://doi.org/10.1155/2014/318481

    work page doi:10.1155/2014/318481 2014

  24. [24]

    Pharmacodynam- ics of subcutaneous recombinant human interleukin-10 in healthy volunteers

    Huhn RD, Radwanski E, Gallo J, Affrime MB, Sabo R, Gonyo G, et al. Pharmacodynam- ics of subcutaneous recombinant human interleukin-10 in healthy volunteers. Clinical Pharma- cology & Therapeutics. 1997 Aug;62(2):171–180. Available from:https://doi.org/10.1016/ S0009-9236(97)90065-5

    work page 1997

  25. [25]

    Experimental Medicine Study to Measure Immune Checkpoint Receptors PD-1 and GITR Turnover Rates In Vivo in Humans

    Lassman ME, Chappell DL, McAvoy T, Cheng A, de Alwis DP, Pruitt SK, et al. Experimental Medicine Study to Measure Immune Checkpoint Receptors PD-1 and GITR Turnover Rates In Vivo in Humans. Clinical Pharmacology & Therapeutics. 2021 Feb;109(6):1575–1582. Available from: https://doi.org/10.1002/cpt.2129

    work page doi:10.1002/cpt.2129 2021

  26. [26]

    Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response

    Li H, Yu J, Liu C, Liu J, Subramaniam S, Zhao H, et al. Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response. Journal of Pharmacokinetics and Pharmacodynamics. 2017 Jun;44(5):403–414. Available from: https://doi.org/10.1007/s10928-017-9528-y

    work page doi:10.1007/s10928-017-9528-y 2017

  27. [27]

    Semimechanistically Based Modeling of Pembrolizumab Time-Varying Clearance Using 4 Longitudinal Covariates in Patients With Non–Small Cell Lung Cancer

    Li H, Sun Y, Yu J, Liu C, Liu J, Wang Y. Semimechanistically Based Modeling of Pembrolizumab Time-Varying Clearance Using 4 Longitudinal Covariates in Patients With Non–Small Cell Lung Cancer. Journal of Pharmaceutical Sciences. 2019 Jan;108(1):692–700. Available from:https: //doi.org/10.1016/j.xphs.2018.10.064

    work page doi:10.1016/j.xphs.2018.10.064 2019

  28. [28]

    Model-Based Char- acterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors

    Ahamadi M, Freshwater T, Prohn M, Li C, de Alwis D, de Greef R, et al. Model-Based Char- acterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors. CPT: Pharmacometrics & Systems Pharmacology. 2016 Nov;6(1):49–57. Available from:https://doi.org/10.1002/psp4.12139. 36

    work page doi:10.1002/psp4.12139 2016

  29. [29]

    Mechanisms Controlling PD-L1 Expression in Cancer

    Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms Controlling PD-L1 Expression in Cancer. Molecular Cell. 2019 Nov;76(3):359–370. Available from:https://doi.org/10.1016/ j.molcel.2019.09.030

    work page 2019

  30. [30]

    Visualizing the First 50 Hr of the Primary Immune Response to a Soluble Antigen

    Catron DM, Itano AA, Pape KA, Mueller DL, Jenkins MK. Visualizing the First 50 Hr of the Primary Immune Response to a Soluble Antigen. Immunity. 2004 Sep;21(3):341–347. Available from: https://doi.org/10.1016/j.immuni.2004.08.007

    work page doi:10.1016/j.immuni.2004.08.007 2004

  31. [31]

    Real-time tracking of cell cycle progression during CD8+ effector and memory T-cell differentiation

    Kinjyo I, Qin J, Tan SY, Wellard CJ, Mrass P, Ritchie W, et al. Real-time tracking of cell cycle progression during CD8+ effector and memory T-cell differentiation. Nature Communications. 2015 Feb;6(1). Available from:https://doi.org/10.1038/ncomms7301

    work page doi:10.1038/ncomms7301 2015

  32. [32]

    Heritable changes in division speed accompany the diversification of single T cell fate

    Plambeck M, Kazeroonian A, Loeffler D, Kretschmer L, Salinno C, Schroeder T, et al. Heritable changes in division speed accompany the diversification of single T cell fate. Proceedings of the National Academy of Sciences. 2022 Feb;119(9). Available from: https://doi.org/10.1073/ pnas.2116260119

    work page 2022

  33. [33]

    Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells

    Kaech SM, Ahmed R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells. Nature Immunology. 2001 May;2(5):415–422. Available from: https://doi.org/10.1038/87720

    work page doi:10.1038/87720 2001

  34. [34]

    Quantitating the Magnitude of the Lymphocytic Choriomeningitis Virus-Specific CD8 T-Cell Response: It Is Even Bigger than We Thought

    Masopust D, Murali-Krishna K, Ahmed R. Quantitating the Magnitude of the Lymphocytic Choriomeningitis Virus-Specific CD8 T-Cell Response: It Is Even Bigger than We Thought. Journal of Virology. 2007 Feb;81(4):2002–2011. Available from: https://doi.org/10.1128/ jvi.01459-06

    work page 2007

  35. [35]

    Defining ‘T cell exhaustion’

    Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, et al. Defining ‘T cell exhaustion’. Nature Reviews Immunology. 2019 Sep;19(11):665–674. Available from:https://doi.org/10. 1038/s41577-019-0221-9

    work page 2019

  36. [36]

    CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer

    McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. Annual Review of Immunology. 2019 Apr;37(1):457–495. Available from: https://doi.org/10.1146/annurev-immunol-041015-055318

    work page doi:10.1146/annurev-immunol-041015-055318 2019

  37. [37]

    Two Distinct Stages in the Transition from Naive CD4 T Cells to Effectors, Early Antigen-Dependent and Late Cytokine-Driven Expansion and Differentiation

    Jelley-Gibbs DM, Lepak NM, Yen M, Swain SL. Two Distinct Stages in the Transition from Naive CD4 T Cells to Effectors, Early Antigen-Dependent and Late Cytokine-Driven Expansion and Differentiation. The Journal of Immunology. 2000 Nov;165(9):5017–5026. Available from: https://doi.org/10.4049/jimmunol.165.9.5017

    work page doi:10.4049/jimmunol.165.9.5017 2000

  38. [38]

    Effector and memory T-cell differentiation: implications for vaccine development

    Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nature Reviews Immunology. 2002 Apr;2(4):251–262. Available from: https://doi.org/10.1038/nri778

    work page doi:10.1038/nri778 2002

  39. [39]

    Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory

    Homann D, Teyton L, Oldstone MBA. Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory. Nature Medicine. 2001 Aug;7(8):913–919. Available from: https://doi.org/10.1038/90950

    work page doi:10.1038/90950 2001

  40. [40]

    Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice

    Darrasse-Jèze G, Bergot AS, Durgeau A, Billiard F, Salomon BL, Cohen JL, et al. Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. Journal of Clinical Investigation. 2009 Aug. Available from: https://doi.org/10.1172/JCI36628. 37

    work page doi:10.1172/jci36628 2009

  41. [41]

    Optimisation of neoadjuvant pembrolizumab therapy for locally ad- vanced MSI-H/dMMR colorectal cancer using data-driven delay integro-differential equations

    Hawi G, Kim PS, Lee PP. Optimisation of neoadjuvant pembrolizumab therapy for locally ad- vanced MSI-H/dMMR colorectal cancer using data-driven delay integro-differential equations

    work page

  42. [42]

    Optimisation of neoadjuvant pembrolizumab therapy for locally advanced MSI-H/dMMR colorectal cancer using data-driven delay integro-differential equations

    arXiv:2411.12123 [q-bio.CB]. Available from: https://doi.org/10.48550/arXiv.2411. 12123

    work page internal anchor Pith review Pith/arXiv arXiv doi:10.48550/arxiv.2411

  43. [43]

    Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression

    Gastl GA, Abrams JS, Nanus DM, Oosterkamp R, Silver J, Liu F, et al. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. International Journal of Cancer. 1993 Aug;55(1):96–101. Available from: https://doi.org/10.1002/ijc. 2910550118

    work page doi:10.1002/ijc 1993

  44. [44]

    Contact-dependent Stimulation and Inhibi- tion of Dendritic Cells by Natural Killer Cells

    Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent Stimulation and Inhibi- tion of Dendritic Cells by Natural Killer Cells. The Journal of Experimental Medicine. 2002 Feb;195(3):335–341. Available from:https://doi.org/10.1084/jem.20010934

    work page doi:10.1084/jem.20010934 2002

  45. [45]

    Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma Patients

    Verdijk P, Aarntzen EHJG, Lesterhuis WJ, Boullart ACI, Kok E, van Rossum MM, et al. Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma Patients. Clinical Cancer Research. 2009 Apr;15(7):2531–2540. Available from: https://doi.org/10.1158/1078-0432.CCR-08-2729

    work page doi:10.1158/1078-0432.ccr-08-2729 2009

  46. [46]

    Dictionary of immune responses to cytokines at single-cell resolution

    Cui A, Huang T, Li S, Ma A, Pérez JL, Sander C, et al. Dictionary of immune responses to cytokines at single-cell resolution. Nature. 2023 Dec;625(7994):377–384. Available from:https: //doi.org/10.1038/s41586-023-06816-9

    work page doi:10.1038/s41586-023-06816-9 2023

  47. [47]

    Regulatory T cells converted from Th1 cells in tumors suppress cancer immunity via CD39

    Tan SN, Hao J, Ge J, Yang Y, Liu L, Huang J, et al. Regulatory T cells converted from Th1 cells in tumors suppress cancer immunity via CD39. Journal of Experimental Medicine. 2025 Feb;222(4). Available from:https://doi.org/10.1084/jem.20240445

    work page doi:10.1084/jem.20240445 2025

  48. [48]

    Multiparameter Flow Cytometry Assay for Quantification of Immune Cell Subsets, PD-1 Expression Levels and PD-1 Receptor Occupancy by Nivolumab and Pembrolizumab

    Pluim D, Ros W, Miedema IHC, Beijnen JH, Schellens JHM. Multiparameter Flow Cytometry Assay for Quantification of Immune Cell Subsets, PD-1 Expression Levels and PD-1 Receptor Occupancy by Nivolumab and Pembrolizumab. Cytometry Part A. 2019 Aug;95(10):1053–1065. Available from: https://doi.org/10.1002/cyto.a.23873

    work page doi:10.1002/cyto.a.23873 2019

  49. [49]

    Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor 38 prognosis in digestive cancers

    Liu Y, Cheng Y, Xu Y, Wang Z, Du X, Li C, et al. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. Oncogene. 2017 Jul;36(44):6143–6153. Available from:https: //doi.org/10.1038/onc.2017.209

    work page doi:10.1038/onc.2017.209 2017

  50. [50]

    Using quantitative systems pharmacology modeling to optimize combination therapy of anti-PD-L1 checkpoint inhibitor and T cell engager

    Anbari S, Wang H, Zhang Y, Wang J, Pilvankar M, Nickaeen M, et al. Using quantitative systems pharmacology modeling to optimize combination therapy of anti-PD-L1 checkpoint inhibitor and T cell engager. Frontiers in Pharmacology. 2023 Jun;14. Available from:https://doi.org/10. 3389/fphar.2023.1163432

    work page arXiv 2023

  51. [51]

    Classification of PD-L1 expression in various cancers and macrophages based on immunohistocytological analysis

    Saito Y, Fujiwara Y, Shinchi Y, Mito R, Miura Y, Yamaguchi T, et al. Classification of PD-L1 expression in various cancers and macrophages based on immunohistocytological analysis. Cancer Science. 2022 Jun;113(9):3255–3266. Available from:https://doi.org/10.1111/cas.15442

    work page doi:10.1111/cas.15442 2022

  52. [52]

    Flow cytometry detec- tion of cell type-specific expression of programmed death receptor ligand-1 (PD-L1) in colorectal cancer specimens

    Saito A, Tojo M, Kumagai Y, Ohzawa H, Yamaguchi H, Miyato H, et al. Flow cytometry detec- tion of cell type-specific expression of programmed death receptor ligand-1 (PD-L1) in colorectal cancer specimens. Heliyon. 2021 Jan;7(1):e05880. Available from:https://doi.org/10.1016/ j.heliyon.2020.e05880. 38

    work page 2021

  53. [53]

    PD-L1+ and XCR1+ dendritic cells are region-specific regulators of gut homeostasis

    Moreira TG, Mangani D, Cox LM, Leibowitz J, Lobo ELC, Oliveira MA, et al. PD-L1+ and XCR1+ dendritic cells are region-specific regulators of gut homeostasis. Nature Communications. 2021 Aug;12(1). Available from:https://doi.org/10.1038/s41467-021-25115-3

    work page doi:10.1038/s41467-021-25115-3 2021

  54. [54]

    Cancer-associated fibroblasts: tumor defenders in radiation therapy

    Zhang Y, Lv N, Li M, Liu M, Wu C. Cancer-associated fibroblasts: tumor defenders in radiation therapy. Cell Death & Disease. 2023 Aug;14(8). Available from: https://doi.org/10.1038/ s41419-023-06060-z. 39

    work page 2023